Monitoring ctDNA to predict ovarian cancer recurrence after surgery
Dynamic Monitoring of ctDNA Predicts Recurrence of Advanced Ovarian Cancer After Primary Treatments
This study is testing if tracking a specific type of DNA in the blood can help predict if ovarian cancer will come back after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06025045 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on ovarian cancer patients who have undergone primary debulking surgery (PDS) or interval debulking surgery (IDS). It aims to utilize dynamic monitoring of circulating tumor DNA (ctDNA) to detect minimal residual disease and predict the recurrence of ovarian cancer post-surgery. By analyzing surgical tissue samples and monitoring ctDNA status during and after adjuvant chemotherapy, the study seeks to establish the predictive value of ctDNA in determining treatment efficacy and recurrence risk. The findings could help tailor adjuvant treatment cycles based on individual patient responses.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with stage IIIC-IVA ovarian cancer who are willing to undergo surgery.
Not a fit: Patients with other tumors detected in the last 5 years or those who have received prior neoadjuvant chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans and improved outcomes for ovarian cancer patients.
How similar studies have performed: While the use of ctDNA monitoring is gaining traction, this specific application in predicting ovarian cancer recurrence is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ≥ 18 years old. 2. Patients diagnosed with stage IIIC-IVA ovarian cancer through pathological examination. 3. The participant has read and fully understands the patient information, and has signed the informed consent form. 4. The patient is willing to undergo primary debulking surgery (PDS) or interval debulking surgery（IDS）. - Exclusion Criteria: 1. Other tumors have been detected within the last 5 years. 2. Organ transplant recipients or those who previously had non-autologous (allogeneic) bone marrow or stem cell transplants. 3. Patients was deemed unsuitable to participate in this study by other researchers. 4. Patients who have previously received neoadjuvant chemotherapy or targeted therapy.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-Sen Memorial Hospital — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jing Li, Prefessor
- Email: lijing228@mail.sysu.edu.cn
- Phone: 15915893493
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.